DDInter1607 DDInter1588
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Tuberculin purified protein derivative {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Ritonavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Indinavir
Indinavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Ribociclib
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Ribociclib
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ritonavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Ribociclib
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ritonavir (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Indinavir (Compound) and Indinavir may lead to a major life threatening interaction when taken with Ribociclib